Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MULTIDOLLAR$$$$$$. it's written on the wall
-countdown -The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM). The application also requests to be considered under the MHRA's rapid 150-day review pathway, which the agency has established for new medicines for serious unmet medical needs.
Advent is now licensed for Storage, Distribution, and Import Human Tissue
LAST UPDATED ON 20 DEC 2023
https://www.hta.gov.uk/professional/establishments/advent-bioservices-ltd
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-advent-bioservices-announce-receipt-of-license-for-commercial-manufacturing-at-sawston-uk-facility-301776725.html
first rule: foremost get off OTC
strength and courage-The cost of the vaccine is £25,000 per dose, with a 3-dose initial minimum.
The cost of the vaccine is £25,000 per dose, with a 3-dose initial minimum.
— rj (@sharpie510) December 19, 2023
New pricing? Pay as you go seems better for patients. And why not? $NWBO is confident the vaccine works.
💪
The DCVax® Platform For All Solid Tumor Cancers#dcvax #Glioblastomahttps://t.co/aDV0Ihiuzw
How Moderna is Helping Advance the Fight Against Cancer
https://www.modernatx.com/media-center/all-media/blogs/insight-report
go on like this$$$$$$
We can't think of a better person to close out our 2023 WINS Woman of the Month features than Dr. Linda Liau!
— WINS Neurosurgery (@WINSneurosurge1) December 15, 2023
Dr. Liau is #MD, #PhD, #MBA, #DepartmentChair, & Executive Medical Director of @UCLANsgy 😱👏#Neurosurgery #WINSxWOM #WomenInNeurosurgery #WomenInSTEM pic.twitter.com/izCnVpsV8J
A personalized approach to treating cancer
Considering the candidate's progress in clinical trials and Moderna's additional work to prepare it for regulatory review, mRNA-4157 could become another near- to medium-term launch. The product may stand out because it's designed to specifically attack each patient's tumor type. So far, this personalized approach is clearly producing positive results; if this continues, the eventual product could be a game changer in the world of oncology.
Though two other RSV vaccines exist on the commercial market, Moderna's would be the only one available in a prefilled syringe; this ease of use could give it the upper hand. If all goes well during the regulatory review, Moderna may become a two-product company in a matter of months,,,,,,,
Thirteen percent of patients treated with the vaccine survived at least five years from diagnosis compared to 5.7% in the control group, with the longest survivor surpassing eight years. Patients with methylated MGMT gene who were treated with the vaccine survived 30.2 months on average from randomization in the trial (33 months from surgery) compared to 21.3 months for the control group.
Patient case study
King's patient, Nigel French, 53, from Whitstable in Kent, was diagnosed with a glioblastoma in 2015 after suffering a nocturnal seizure. Having been referred to King's for surgery, he was offered enrolment onto the DC Vax trial, to which he agreed. Seven years later, he is still in remission and is thankful to have had the opportunity to trial the vaccine.
Nigel said, "I'm very grateful to the team at King's for offering me this lifeline. Although I can't be certain as to whether I received DC Vax or the placebo, I believe the treatment I received, along with remaining positive, saved my life."
https://medicine.net/news/Worldmedicine/5225.html
Landmark Melanoma Vaccine Could Be Available in Just 2 Years
In a study involving 157 people with advanced melanoma, the Moderna vaccine in combination with Merck's immunotherapy drug Keytruda reduced the risk of recurrence or death by 49 percent over a period of three years, compared with Keytruda alone.
"We have one in two people, compared to the best product on the market, who survive," he said, "which in oncology is huge."
https://www.sciencealert.com/landmark-melanoma-vaccine-could-be-available-in-just-2-years
Congratulations to Dr. Linda Liau & Dr. Timothy Cloughesy, Co-Directors of the UCLA Brain Tumor Center, who recently received a $500,000 donation from Heart of the Brain, a nonprofit organization dedicated to raising critical funds to find a cure for brain cancer.@UCLANeurology pic.twitter.com/Jyy0ReAyI5
— UCLA Neurosurgery 🧠 (@UCLANsgy) December 15, 2023
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
Moderna has submitted marketing authorizations globally for mRNA-1345 and continues to prepare for an expected 2024 marketing launch
https://www.nejm.org/doi/full/10.1056/NEJMoa2307079
the Keynote-942/mRNA-4157-P201 study was the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial and the first combination therapy to show a significant benefit over Keytruda alone in adjuvant melanoma!
$NWBO patent application "Approved for Allowance" - 🇨🇦 CA2509058 - "Administration of dendritic cells partially matured in vitro for the treatment of tumors"
— Henry (@HenryMuney) December 14, 2023
Next: Notice of allowance, payment, and grant.https://t.co/KDxjwYt0dq pic.twitter.com/QIC1sZL0J4
not bad-------At a three-year follow-up with trial participants who had had a stage III or IV melanoma fully removed but were at high risk of the cancer coming back, those who got the vaccine from Moderna and Merck along with Merck’s Keytruda immunotherapy had a 49% lower risk of recurrence or death and a 62% lower risk of distant tumor cell spread or death compared with those who got Keytruda alone
Merck and Moderna are testing the combination in other cancers where Keytruda is already used. Earlier this week, the companies said they began a late-stage trial of the combination in lung cancer patients
Stéphane Bancel said the companies want to talk to regulators about getting the skin cancer vaccine approved on a faster timeline. The cancer vaccine could launch as early as 2025, Bancel said in an interview with CNBC.
“If you look at the next 24 months, it’s going to be very dense news flow, very dense product launches,” he said.
He added that the manufacturing for the personalized vaccine, which is produced based on each recipient's DNA, has been reduced to just 30 days from diagnosis to treatment
Moderna CEO talks skin cancer vaccine
https://finance.yahoo.com/video/moderna-ceo-discusses-talks-skin-175754434.html
these are things that can happen....
this is the game------Adverse events observed with mRNA-4157 (V940) in KEYNOTE-942 remain consistent with those previously reported. At a median planned follow-up of approximately three years, the number of patients reporting treatment-related Grade ≥ 3 adverse events were similar between the arms (25% for mRNA-4157 (V940) in combination with KEYTRUDA vs 20% for KEYTRUDA alone). The most common adverse events of any grade attributed to mRNA-4157 (V940) were fatigue (60.6%), injection site pain (56.7%), and chills (49%).
you feel the bomb??? the music has changed... First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
https://ir.carismatx.com/news-releases/news-release-details/first-vivo-car-m-lead-candidate-nominated-under-carisma-moderna
great news$$$$$$$-- Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
https://investors.modernatx.com/news/news-details/2023/Moderna-And-Merck-Announce-mRNA-4157-V940-In-Combination-with-KeytrudaR-Pembrolizumab-Demonstrated-Continued-Improvement-in-Recurrence-Free-Survival-and-Distant-Metastasis-Free-Survival-in-Patients-with-High-Risk-Stage-IIIIV-Melanoma-Following-Comple/default.aspx
it will still be on the market?
this is the question
so what? Pathos has established a separate, wholly-owned subsidiary to complete the Transaction. Following the tender offer closing, this subsidiary will be merged into Rain with Rain as the surviving entity of the merger, which will then operate as a separate, wholly-owned subsidiary of Pathos. If the tender offer is successful, the Transaction is expected to close in January 2024.
ABC News’ Dr. Jennifer Ashton explains a new breast cancer trial out of the Cleveland Clinic that shows promising phase one results.
https://abcnews.go.com/GMA/Wellness/video/new-study-breast-cancer-vaccine-105544652
I agree 1000%
let's try to resist...in this, sea of ??sharks!
let's try to make money... my friend$$$$$$ it's not easy!
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Changes-to-Commercial-Organization-to-Prepare-for-Multiple-Product-Launches-in-2024-and-2025/default.aspx
if you say so. let's go$
I post little about.only ^RNA
$NWBO can become a big winner...
you made a mistake....
remember that-$- Northwest Biotherapeutics World's First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland
https://www.biospace.com/article/releases/northwest-biotherapeutics-world-s-first-therapeutic-vaccine-for-brain-cancer-commercially-available-to-patients-in-switzerland-/
Nevertheless, the future pushes on....
https://abcnews.go.com/GMA/Wellness/breast-cancer-vaccine-now-early-clinical-trials/story?id=105550075
The companies plan to continue expansion of the comprehensive clinical development program for V940 (mRNA-4157) to additional tumor types.